Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MDCO Medicines (MDCO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Medicines Stock (NASDAQ:MDCO) 30 days 90 days 365 days Advanced Chart Get Medicines alerts:Sign Up Key Stats Today's Range$84.90▼$84.9050-Day Range$84.90▼$84.9052-Week Range$17.81▼$84.98VolumeN/AAverage Volume9.55 million shsMarket Capitalization$6.77 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewThe Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.Read More… Receive MDCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address MDCO Stock News HeadlinesRevolution Medicines Inc (RVMD) Announces Upcoming Financial Results ReleaseFebruary 20 at 8:30 PM | gurufocus.comRevolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025February 19 at 5:08 PM | investing.com$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.February 22, 2025 | Altimetry (Ad)TYK Medicines Completes H Share Full CirculationFebruary 18, 2025 | tipranks.com3D Medicines Inc. Reports Resolution in Civil Proceedings, Ensures Continued OperationsFebruary 17, 2025 | tipranks.comCautious Optimism: Hold Rating Given to Blueprint Medicines Amid Financial Performance Concerns and Slower Ayvakit Growth ProjectionsFebruary 17, 2025 | tipranks.comSteven Cohen's Strategic Acquisition in Praxis Precision Medicines IncFebruary 15, 2025 | gurufocus.comCormorant Asset Management's Strategic Acquisition of Praxis Precision Medicines SharesFebruary 14, 2025 | gurufocus.comSee More Headlines MDCO Stock Analysis - Frequently Asked Questions How were Medicines' earnings last quarter? The Medicines Company (NASDAQ:MDCO) issued its quarterly earnings data on Wednesday, October, 30th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.12. What other stocks do shareholders of Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medicines investors own include Bristol-Myers Squibb (BMY), NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), AbbVie (ABBV), Alibaba Group (BABA) and Salesforce (CRM). Company Calendar Last Earnings10/30/2019Today2/22/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MDCO CUSIP58468810 CIK1113481 Webwww.themedicinescompany.com Phone973-290-6000FaxN/AEmployees62Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,160,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-25.70% Debt Debt-to-Equity Ratio21.45 Current Ratio0.77 Quick Ratio0.77 Sales & Book Value Annual Sales$6.14 million Price / Sales1,102.36 Cash FlowN/A Price / Cash FlowN/A Book Value($0.30) per share Price / Book-283.00Miscellaneous Outstanding Shares79,723,000Free FloatN/AMarket Cap$6.77 billion OptionableOptionable Beta1.10 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:MDCO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Medicines Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
